Mineralys Therapeutics In... (MLYS)
NASDAQ: MLYS
· Real-Time Price · USD
14.51
0.38 (2.69%)
At close: Aug 15, 2025, 3:59 PM
14.52
0.10%
After-hours: Aug 15, 2025, 04:20 PM EDT
Mineralys Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
Revenue | n/a | n/a | 34K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 15K | 17K | 11K | 9K | 8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | -15K | 17K | -11K | -9K | -8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -46.75M | -44.45M | -51.77M | -60.11M | -45.17M | -35.36M | -27.71M | -26.27M | -15.73M | -14.94M | -10.01M | -7.42M | -6.48M | -7.57M | -7.08M |
Interest Income | 3.47M | 2.24M | 2.81M | 3.77M | 4.15M | 3.85M | 3.32M | 3.51M | 3.59M | 2.33M | 935K | 741K | n/a | n/a | n/a |
Pretax Income | -43.27M | -42.21M | -48.95M | -56.34M | -41.01M | -31.51M | -24.39M | -22.76M | -12.14M | -12.61M | -9.07M | -6.68M | -6.48M | -7.57M | -7.08M |
Net Income | -43.27M | -42.21M | -48.95M | -56.34M | -41.01M | -31.51M | -24.39M | -22.76M | -12.14M | -12.61M | -9.07M | -6.68M | -6.48M | -7.57M | -7.08M |
Selling & General & Admin | 8.47M | 6.57M | 7.2M | 6.12M | 5.89M | 4.6M | 4.03M | 3.77M | 3.85M | 2.65M | 2.19M | 1.36M | 884K | 791K | 467K |
Research & Development | 38.28M | 37.88M | 44.57M | 53.98M | 39.27M | 30.75M | 23.68M | 22.5M | 11.88M | 12.29M | 7.82M | 6.06M | 5.59M | 6.78M | 6.62M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 46.75M | 44.45M | 51.77M | 60.11M | 45.17M | 35.35M | 27.71M | 26.27M | 15.73M | 14.94M | 10.01M | 7.42M | 6.48M | 7.57M | 7.08M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | -8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 46.75M | 44.45M | 51.79M | 60.11M | 45.17M | 35.36M | 27.71M | 26.27M | 15.73M | 14.94M | 10.01M | 7.42M | 6.48M | 7.57M | 7.08M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 65.45M | 53.16M | 49.96M | 49.81M | 49.36M | 44.9M | 40.09M | 39.93M | 39.76M | 24.76M | 5.21M | 5.18M | 5.14M | 5.12M | 5.06M |
Shares Outstanding (Diluted) | 65.45M | 53.16M | 49.96M | 49.82M | 49.36M | 44.9M | 40.09M | 39.93M | 39.75M | 24.76M | 5.21M | 5.18M | 5.15M | 5.12M | 5.06M |
EPS (Basic) | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.7 | -0.61 | -0.57 | -0.31 | -0.51 | -1.74 | -1.29 | -1.26 | -1.48 | -1.4 |
EPS (Diluted) | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.7 | -0.61 | -0.57 | -0.31 | -0.51 | -1.74 | -1.29 | -1.26 | -1.48 | -1.4 |
EBITDA | -46.75M | -44.45M | -51.75M | -60.09M | -45.16M | -35.35M | -27.71M | -26.27M | -15.73M | -14.94M | -10.01M | n/a | -6.48M | n/a | -7.08M |
EBIT | -43.27M | -44.45M | -51.77M | -60.11M | -45.17M | -35.36M | -27.71M | -26.27M | -15.73M | -14.94M | -10.01M | -7.42M | -6.48M | -7.57M | -7.08M |
Depreciation & Amortization | n/a | 15K | 15K | 11K | 9K | 8K | 43.81K | -39.59K | 122.08K | n/a | 10.01M | 7.42M | 6.48M | 7.57M | 7.08M |